5Kimball AB, Gordon KB, Langley RG, et al. Safey and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal anti- body,in the treatment of moderate to severe chronic plaque pso- riasis:results of a randomized, placebo-controlled,phase 2 trial[J]. Arch Dermatol, 2008, 144(2): 200-207.
6Korman BD, Tyler KL, Korman N2. Progressive multifocal leukoencephalopathy, efalizumab, and immunosuppression: a cau- tionary tale for dermatologists[J]. Arch Dermatol, 2009, 145:(8) 937-942.
7Van de Kerkhnf P, Griffths CE, Christophers E, et al. Alefacept in the treatment of psoriasis in patiats for whom conventional therapies are inadrquete[J]. Dermatology, 2005, 211(3): 256-263.
8Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial[J]. Lancet, 2001, 357(9271): 1842-1847.
9Fortaleza GT, Brito Mde F, Santos JB. Splenic tuberculosis dur- ing psoriasis treatment with infliximab [J]. An Bras Dermatol, 2009, 84(4): 420-424.
10Turner D, Picot J, Cooper K, et al. Adalimumab for the treat- ment of psoriasis[J]. Health Technology Assessment, 2009, 13(2): 49-54.
2Krueger G,Koo J,Lebwohl M,et al.The impact of psoriasis on quality of life:results of a 1998 National Psoriasis Foundation patientmembership survey[J].Arch Dermatol,2001,37(3):280-284.
3Koo J.Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment[J].Dermatol Clin,1996,14(3):485-496.
4Koo J.Population-based epidemiologic study d psoriasis with emphasis on quality of life assessment[J].Dermatol Clin,1996,14(3):485-96.
5Langley BG,Krueger GG,Griffiths CE.Psoriasis:epidemiology,clinical features,and quality of life[J].Ann Rheum Dis,2005,64(2):18-23.
6Brasthen LR,Botten G,Bjerkedal T.Prevalence of psoriasis in Norway[J].Acta Derm Venereol (Stockh),1989,Suppl 142:5-8.
7Ferrándiz C,Bordas X,Garcia-Patos V,et al.Prevalence of psoriasis in Spain (Epiderma Project:phase Ⅰ)[J].J Eur Acad Dermatol Venereol,2001,15 (1):20-23.
8Gelfand JM,Weinstein R,Porter SB,et al.Prevalence and treatment of psoriasis in the United Kingdom:a population-based study[J].Arch Dermatol,2005,141(12):537-541.
9钱戊春.新疆地区银屑病调查报告.新疆医学院学报,1978,2:204-204.
10Mrowietz U, Zhu K, Christophers E. Treatment of severe psoriasis with anti-CD25 monoclonal antibodies.Arch Dermatol, 2000,136 : 675-676.
